|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1982-9-10
|
|
pubmed:abstractText |
Twenty evaluable patients with advanced islet cell carcinoma were treated with doxorubicin at a dosage of 60 mg/m2 every 3-4 weeks. Toxicity was clinically tolerable and characteristic of doxorubicin therapy. Although all patients had previously been treated with other chemotherapy regiments, four (20%) had objective therapeutic responses persisting for 2-301/2 months. Doxorubicin has definite therapeutic activity in islet cell carcinoma and is currently being evaluated in combination chemotherapy regimens.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0361-5960
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1567-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:6284361-Adenoma, Islet Cell,
pubmed-meshheading:6284361-Adolescent,
pubmed-meshheading:6284361-Adult,
pubmed-meshheading:6284361-Aged,
pubmed-meshheading:6284361-Doxorubicin,
pubmed-meshheading:6284361-Drug Evaluation,
pubmed-meshheading:6284361-Female,
pubmed-meshheading:6284361-Follow-Up Studies,
pubmed-meshheading:6284361-Humans,
pubmed-meshheading:6284361-Insulinoma,
pubmed-meshheading:6284361-Male,
pubmed-meshheading:6284361-Middle Aged,
pubmed-meshheading:6284361-Neoplasm Metastasis,
pubmed-meshheading:6284361-Pancreatic Neoplasms
|
|
pubmed:year |
1982
|
|
pubmed:articleTitle |
Phase II trial of doxorubicin therapy for advanced islet cell carcinoma.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
